The treatment landscape for unresectable hepatocellular carcinoma has undergone profound change over the past 5 years, presenting both unprecedented opportunities and complex decision-making challenge...

Background Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have shown promising effects on liver histology in phase 2 trials enrolling patients with metabolic dysfunction-associated steatotic liv...